Core Viewpoint - The company, Jindalai (688057.SH), is optimistic about the development prospects of medical robotics technology and plans to optimize its industrial structure to enhance risk resistance and cultivate new profit growth points through a strategic investment in Zhongke Hongtai Medical Technology Co., Ltd. [1] Group 1: Investment Details - The company intends to invest 30 million yuan in Zhongke Hongtai, with 1.9586895 million yuan allocated for subscribing to the new registered capital and the remaining 28.0413105 million yuan added to capital reserves [1] - Upon completion of the transaction, the company will hold a 10% equity stake in Zhongke Hongtai [1] Group 2: Product Advantages - Zhongke Hongtai's self-developed multi-channel vascular intervention surgical robot features significant advantages, including a bionic design that allows simultaneous rotation and pushing of guidewires [1] - The dual-channel design enables the operation of two guidewires and two balloon/stent catheters simultaneously, along with force feedback functionality [1] - The surgical robot can perform remote surgeries, provide full-process robotic assistance, and collect data, surpassing existing industry standards [1] Group 3: Strategic Goals - The core team of Zhongke Hongtai possesses deep technical expertise and original research capabilities, offering differentiated innovation and technological breakthroughs [2] - The investment aims to expand the company's business, enhance profitability, and improve overall competitiveness and influence, promoting sustainable development [2]

Core Viewpoint - The company, Jindalai (688057.SH), is optimistic about the development prospects of medical robotics technology and plans to optimize its industrial structure to enhance risk resistance and cultivate new profit growth points through a capital increase in Beijing Zhongke Hongtai Medical Technology Co., Ltd. [1][2] Group 1: Investment Details - The company intends to invest 30 million yuan in Zhongke Hongtai, with 1.9586895 million yuan allocated for subscribing to the new registered capital and the remaining 28.0413105 million yuan added to the capital reserve [1] - After the transaction, the company will hold a 10% stake in Zhongke Hongtai [1] Group 2: Product Advantages - Zhongke Hongtai's self-developed multi-channel vascular interventional surgical robot features significant advantages, including bionic design for simultaneous wire rotation and pushing operations, dual-channel design for operating two wires and two balloon/stent catheters simultaneously, and force feedback functionality [1] - The surgical robot can perform remote surgeries, full-process robotic assistance, and data collection, surpassing existing industry standards [1] Group 3: Strategic Goals - The core team of Zhongke Hongtai possesses deep technical expertise and original research and development capabilities, offering differentiated innovation and technological breakthroughs [2] - The investment aims to expand the company's business, enhance profitability, improve overall competitiveness and influence, and promote sustainable development [2]